Freelance for Medscape Medical News, Smithsonian.com
Alicia Ault is a freelance writer who covers a wide range of topics including health, science, medicine, art, culture, sports, and life. She has contributed to publications such as Medscape Medical News and Smithsonian.com. With a passion for music, food, and tennis, Alicia brings a diverse perspective to her writing.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Alicia Ault's articles predominantly cover healthcare and pharmaceutical topics, with a focus on data-driven insights, government announcements, and legal policy regulations. She appears to be particularly interested in articles that cite reliable data sources or that involve government announcements related to the healthcare industry.
As such, she would likely respond well to pitches from experts who can provide analysis or commentary based on credible data sources within the healthcare and pharmaceutical sectors. Additionally, professionals with insights into evolving policies or legal implications relating to drug shortages, mental health issues, medical research advancements, substance abuse treatments and healthcare policies could be valuable contributors for her coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
The US Congress has approved a funding increase for the Special Diabetes Program for the first time since 2004, giving additional heft to efforts
The US Food and Drug Administration (FDA) embraced the use of biomarkers and surrogate endpoints in its most recent guidance on developing therapeutics for early Alzheimer's disease (AD).
The FDA embraces the use of biomarkers and surrogate endpoints in its most recent guidance on developing therapeutics for early Alzheimer’s disease.
Industry payments appeared to have been little changed by public reporting in the Open Payments database.
By: Alicia Ault
A review of the federal Open Payments database found that the pharmaceutical and medical device industry paid physicians $12.1 billion over nearly a decade.
The US Food and Drug Administration (FDA) has approved the first-ever prescription app for major depressive disorder (MDD).
The first US clinical guidelines to diagnose and treat attention-deficit/hyperactivity disorder (ADHD) in adults are expected to be released this
Efficacy and safety of the two formulations were directly compared in a randomized, controlled, double-blind study of men with AGA conducted in Brazil.
In October, the US Food and Drug Administration (FDA) pressed pause on a trial studying a new lymphoma drug after a patient died.
Clinical trial holds delay therapies getting to market and may be on the rise in oncology. But there's a lot the public doesn't know about how often these holds happen and why.
(833) 317-6278 
